ALISKIREN HEMIFUMARATE and COUGH

Overview

COUGH is the #9 most commonly reported adverse reaction for ALISKIREN HEMIFUMARATE, manufactured by LXO US Inc.. There are 510 FDA adverse event reports linking ALISKIREN HEMIFUMARATE to COUGH. This represents approximately 2.0% of all 26,137 adverse event reports for this drug.

Patients taking ALISKIREN HEMIFUMARATE who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COUGH is a less commonly reported adverse event for ALISKIREN HEMIFUMARATE, but still significant enough to appear in the safety profile.

Other Side Effects of ALISKIREN HEMIFUMARATE

In addition to cough, the following adverse reactions have been reported for ALISKIREN HEMIFUMARATE:

• NAUSEA — 627 reports
• BLOOD PRESSURE INCREASED — 593 reports
• HEADACHE — 580 reports
• FATIGUE — 578 reports
• ASTHENIA — 561 reports
• FALL — 561 reports
• DIZZINESS — 524 reports
• DYSPNOEA — 514 reports
• MALAISE — 499 reports
• DIARRHOEA — 456 reports

Other Drugs Associated with COUGH

The following drugs have also been linked to cough in FDA adverse event reports:

Does ALISKIREN HEMIFUMARATE cause COUGH?

COUGH has been reported as an adverse event in 510 FDA reports for ALISKIREN HEMIFUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COUGH with ALISKIREN HEMIFUMARATE?

COUGH accounts for approximately 2.0% of all adverse event reports for ALISKIREN HEMIFUMARATE, making it a notable side effect.

What should I do if I experience COUGH while taking ALISKIREN HEMIFUMARATE?

If you experience cough while taking ALISKIREN HEMIFUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages